These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

646 related items for PubMed ID: 17317046

  • 1. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G, Dvorak V, Genazzani AR, Hamann B, Heikkinen J, Mueck AO, Suzin J, Kawakami FT, Ferreira A, Sun D, Arguinzoniz M.
    Maturitas; 2007 Jun 20; 57(2):171-81. PubMed ID: 17317046
    [Abstract] [Full Text] [Related]

  • 2. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E, Holinka CF, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 Jun 20; 42 Suppl 2():388-98. PubMed ID: 9397386
    [Abstract] [Full Text] [Related]

  • 3. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S, Ylikorkala O, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 Jun 20; 42 Suppl 2():376-87. PubMed ID: 9397385
    [Abstract] [Full Text] [Related]

  • 4. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H.
    Menopause; 2007 Jun 20; 14(6):978-84. PubMed ID: 17595593
    [Abstract] [Full Text] [Related]

  • 5. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
    Ross AH, Boyd ME, Colgan TJ, Ferenczy A, Fugere P, Lorrain J.
    Obstet Gynecol; 1993 Nov 20; 82(5):773-9. PubMed ID: 8414325
    [Abstract] [Full Text] [Related]

  • 6. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G, Tugrul S, Uslu H, Pekin O, Eren S.
    Arch Gynecol Obstet; 2006 Feb 20; 273(5):268-73. PubMed ID: 16315025
    [Abstract] [Full Text] [Related]

  • 7. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study.
    Samsioe G, Boschitsch E, Concin H, De Geyter C, Ehrenborg A, Heikkinen J, Hobson R, Arguinzoniz M, Ibarra de Palacios P, Scheurer C, Schmidt G, Estalis 50/140 Study Group.
    Climacteric; 2006 Oct 20; 9(5):368-79. PubMed ID: 17080587
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W, El-Samalouti V, Gerlinger C, Schaefers M.
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec 20; 147(2):195-200. PubMed ID: 19879683
    [Abstract] [Full Text] [Related]

  • 10. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O, Lim P, Caubel P.
    Clin Ther; 2000 May 20; 22(5):622-36. PubMed ID: 10868559
    [Abstract] [Full Text] [Related]

  • 11. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
    Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K.
    Climacteric; 2013 Aug 20; 16(4):490-8. PubMed ID: 23531117
    [Abstract] [Full Text] [Related]

  • 12. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, TOTAL Study Investigators Group.
    BJOG; 2007 Dec 20; 114(12):1522-9. PubMed ID: 17995496
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC.
    Maturitas; 2006 Mar 20; 53(4):413-23. PubMed ID: 16140483
    [Abstract] [Full Text] [Related]

  • 18. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen.
    Rozenberg S, Pornel B, Koninckx PR, Palacios S, Christiansen C.
    Hum Reprod; 2009 Jul 20; 24(7):1739-47. PubMed ID: 19351658
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women.
    Bassol S, Carranza-Lira S, Celis-Gonzalez C, Santoyo S, Murillo A, Martinez N, Santos J, Llaca V, de la Loza FR, Zarain J, da Fonseca AM, Camargos AF, Baracat EC, da Sá MF, Bayo J, Adaro L, Gurucharri C, Murga M, Siseles N, Sayegh F, Tempone A, Tempone LM, Tozzini RI, Boccanera R, Naranjo C, Sanchez F, Gomez G, Blanco S, Reyes-Marquez R, Albrecht G, Rios PC.
    Maturitas; 2005 Mar 14; 50(3):189-95. PubMed ID: 15734600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.